CN108815197A - Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation - Google Patents
Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation Download PDFInfo
- Publication number
- CN108815197A CN108815197A CN201710304838.3A CN201710304838A CN108815197A CN 108815197 A CN108815197 A CN 108815197A CN 201710304838 A CN201710304838 A CN 201710304838A CN 108815197 A CN108815197 A CN 108815197A
- Authority
- CN
- China
- Prior art keywords
- cell
- wall skeleton
- nocardia rubra
- cell wall
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to Lyopgized Nocardia rubra-cell Wall Skeletons as CD4+T cell enhancer of proliferation, CD4+T cell function of surface molecule CD25, CD69 express promotor or CD4+The purposes of T cell TNF-α, IL-5, IL-2 expression promotor.
Description
Technical field
The invention belongs to field of medicaments, and in particular to Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+T cell proliferation promotees
Into the purposes of agent.
Background technique
Nocard's bacillus be it is polymorphic, have that Nocardia is spherical, rod-shaped, Filamentous, thallus size 0.6 × (3~4) micron,
Without motion, some strains are in weak acid-resisting, and obligate aerobic, nutritional requirement is general.Have after being cultivated 3 days on plain agar plate
Visible colonies, bacterium colony projection after 7~10 days, after aerial hyphae is formed, surface is in villiform.Bacterium colony not of the same race has yellow, orange, red
Or the secondary colour of these pigments.G+C gram molecule content in DNA is 60~72%.It is mostly saprophytic bacteria, is present in soil.
Nocardia rubra (Nocardiarubra) is one such actinomyces.Nocardia rubra thallus is fermented, cell is broken
Lyopgized Nocardia rubra-cell Wall Skeleton (hereinafter referred to as Nr-CWS or N-CWS) can be made after broken, proteasome degradation.
Summary of the invention
Present invention discover that Lyopgized Nocardia rubra-cell Wall Skeleton can promote CD4+T cell proliferation promotes CD4+T cell table
The expression of face functional molecular CD25 and CD69 and promotion CD4+The expression of T cell TNF-α, IL-5 and IL-2, and then complete
The present invention.
According to an aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton in preparation for promoting
CD4+Purposes in the drug of T cell proliferation.According to the present invention, the drug can be by promoting CD4+T cell anti-proliferative treatment with
CD4+The relevant disease of T cell, including but not limited to：Such as body local tissue infection caused by the pathogenic microorganism of virus etc.
Or lesion and autoimmune disease.
According to another aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose
CD4+The purposes of T cell enhancer of proliferation.According to the present invention, described " non-treatment purpose " for example promotes CD4 in vitro+T cell
Proliferation.
According to another aspect of the present invention, the present invention provides a kind of external promotion CD4+The method of T cell proliferation,
In, give the CD4 of in vitro culture+T cell Lyopgized Nocardia rubra-cell Wall Skeleton.It is preferred that Lyopgized Nocardia rubra-cell Wall Skeleton
Concentration be 1-60 μ g/ml, further preferred 2-30 μ g/ml, more preferable 3-15 μ g/ml.
According to another aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton in preparation for promoting
CD4+Purposes in the drug of T cell function of surface molecule CD25 or CD69 expression.According to the present invention, the drug can pass through
Promote CD4+T cell function of surface molecule CD25 or CD69 expression treatment and CD4+The relevant disease of T cell, including but not limited to：
Such as body local tissue infection caused by the pathogenic microorganism of virus etc. or lesion and autoimmune disease.
According to another aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose
CD4+The purposes of T cell function of surface molecule CD25 or CD69 expression promotor.According to the present invention, described " non-treatment purpose "
Such as promote CD4 in vitro+T cell function of surface molecule CD25 or CD69 expression.
According to another aspect of the present invention, the present invention provides a kind of external promotion CD4+T cell function of surface molecule
The method of CD25 or CD69 expression, wherein give the CD4 of in vitro culture+T cell Lyopgized Nocardia rubra-cell Wall Skeleton.It is preferred that
The concentration of Lyopgized Nocardia rubra-cell Wall Skeleton is 1-60 μ g/ml, further preferred 2-30 μ g/ml, more preferable 3-15 μ g/ml.
According to another aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton in preparation for promoting
CD4+Purposes in the drug of T cell TNF-α, IL-5 or IL-2 expression.According to the present invention, the drug can pass through promotion
CD4+T cell TNF-α, IL-5 or IL-2 expression treatment and CD4+The relevant disease of T cell, including but not limited to：Such as virus etc.
Pathogenic microorganism caused by body local tissue infection or lesion and autoimmune disease.
According to another aspect of the present invention, the present invention provides Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose
CD4+The purposes of T cell TNF-α, IL-5 or IL-2 expression promotor.According to the present invention, described " non-treatment purpose " for example exists
It is external to promote CD4+T cell TNF-α, IL-5 or IL-2 expression.
According to another aspect of the present invention, the present invention provides a kind of external promotion CD4+T cell TNF-α, IL-5 or IL-
The method of 2 expression, wherein give the CD4 of in vitro culture+T cell Lyopgized Nocardia rubra-cell Wall Skeleton.It is preferred that red promise card
The concentration of Salmonella cell wall skeleton is 1-60 μ g/ml, further preferred 2-30 μ g/ml, more preferable 3-15 μ g/ml.
It will be understood by those skilled in the art that Lyopgized Nocardia rubra-cell Wall Skeleton can it is commercially available or according to this field
The various methods known are prepared.It is preferred that nocardia rubra is that (it is micro- that it was preserved in China on 2 5th, 2002 to Nr-8206
Biological inoculum preservation administration committee common micro-organisms center, deposit number are CGMCC NO.0712).For example, can pass through by
DNA, DNA, RNA, protein, lipoid are removed after nocardia rubra fermentation, Lyopgized Nocardia rubra-cell Wall Skeleton is prepared,
Its principle active component is muramic acid, polysaccharide and mucopeptide, and molecular weight is about 2-20KD.
The present invention confirms that Lyopgized Nocardia rubra-cell Wall Skeleton can promote CD4 by experiment for the first time+T cell proliferation,
Promote CD4+The expression of T cell function of surface molecule CD25 and CD69 and promotion CD4+T cell TNF-α, IL-5 and IL-2
Expression, so that Lyopgized Nocardia rubra-cell Wall Skeleton can be used to treat in vivo and CD4+The related disease of T cell, and
And it can be used to promote CD4 in vitro+T cell proliferation promotes CD4+The expression of T cell function of surface molecule CD25 and CD69, with
And promote CD4+The expression of T cell TNF-α, IL-5 and IL-2.
Detailed description of the invention
Fig. 1 Lyopgized Nocardia rubra-cell Wall Skeleton promotes CD4+T cell proliferation：Figure 1A is 24 hours, and Figure 1B is 48 hours
Fig. 2 Lyopgized Nocardia rubra-cell Wall Skeleton promotes CD4+The expression of T cell function of surface molecule CD25 and CD69：
Fig. 2A 1 is 24 hours streaming figures；Fig. 2A 2 is 24 hours CD25 and CD69 expression comparison；Fig. 2 B1 is 48 hours streaming figures；Fig. 2 B2
For 48 hours CD25 and CD69 expression comparison
Fig. 3 Lyopgized Nocardia rubra-cell Wall Skeleton promotes CD4+The expression of T cell TNF-α, IL-5 and IL-2：Fig. 3 A is
24 hours TNF-α, IL-5 and IL-2 expression comparison；Fig. 3 B is 48 hours TNF-α, IL-5 and IL-2 expression comparison
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.Furthermore, it is to be understood that after having read documented content of the invention, this field skill
Art personnel can make various changes or modifications the present invention, and such equivalent forms equally fall within limited range of the present invention.
Embodiment 1.Nr-CWS promotes CD4+T cell proliferation
1. mouse CD4+T cell is isolated and purified, is cultivated
(1) sterile separating mouse (cleaning grade C57BL/6 mouse, 6-8 week old, female, 18-20 grams of weight, be purchased from Shanghai this
Lake experimental animal Co., Ltd) spleen, prepare single cell suspension；Cell is discarded supernatant to obtain after 1000rpm/min centrifugation 10min
Precipitating；Gained spleen cell precipitating is suspended with 2ml erythrocyte cracked liquid, on ice splitting erythrocyte 5min, and it is slow that the cold PBS of 10ml is added
Fliud flushing, 1000rpm/min discard supernatant to obtain cell precipitation after being centrifuged 5min；It is resuspended in 2ml magnetic bead sorting buffer, adjustment is thin
Born of the same parents' concentration is 1 × 108/ml。
(2) according to StemcellEasySepTMmouse CD4+T cell isolation Kit Beads enrichment operation instruction
Book operating procedure, sterile sorting CD4+T cell and be about 96.3% with flow cytometer detection separating purity.
(3) with addition 10% heat-inactivated fetal bovine serum (FBS) 1640 culture medium of complete RPMI (2mM L-Glutamine,
50 μM of beta -mercaptoethanols, 100U/ml penicillin, 100 μ g/ml streptomysins, 100 μ g/ml kanamycins) suspension fresh separated
CD4+T cell, by 1 × 106/ ml cell density is inoculated with 96 orifice plates (coating anti-CD3 antibody in advance), every 100 μ l of hole, and
Anti-CD28 antibody is added in culture medium；In 37 DEG C, 5%CO2Incubator in cultivate.
2.Nr-CWS promotes CD4+T cell proliferation
CD4+T cell presses 1 × 106/ ml cell density is inoculated with 96 orifice plates, every 100 μ l of hole.In 37 DEG C, 5%CO2Incubator
After middle culture 2 hours, experimental group addition is respectively 1.875 μ g/ml, 3.75 μ g/ml, 7.5 μ g/ with the concentration that culture solution dissolves
The Nr-CWS (Liaoning Ge Ruishite Biology Pharmacy Co., Ltd, similarly hereinafter) of ml, 15 μ g/ml, 30 μ g/ml, 60 μ g/ml, every hole 100
μ l, each concentration set 3 multiple holes.RPMI 1640 culture medium, every 100 μ l of hole, if 3 multiple holes is added in control group.In 37 DEG C, 5%
CO2Incubator in cultivate 24 hours and 48 hours.At last 4 hours of each detection time point, 20 μ l MTS/ were added in every hole
PMS mixed liquor (96 Aqueous One Solution Cell Proliferation Assay kit).Eventually
After only cultivating, the absorbance in each hole, reference wavelength 600nm are measured at enzyme-linked immunosorbent assay instrument OD490nm.
As a result (see Fig. 1, wherein Figure 1A is 24 hours, and Figure 1B is 48 hours) display, Nr-CWS concentration be 7.5 μ g/ml,
When 15 μ g/ml, 30 μ g/ml, 60 μ g/ml, CD4 is handled+After T cell 24 hours, CD4+T cell proliferation is significant compared with the control group
Increase (* p<0.05 or * * p<0.01)；Nr-CWS concentration be 1.875 μ g/ml, 3.75 μ g/ml, 7.5 μ g/ml, 15 μ g/ml,
When 30 μ g/ml, 60 μ g/ml, CD4 is handled+After T cell 48 hours, CD4+T cell proliferation is significant compared with the control group to be increased (#p<
0.001)；Compared with when concentration is 7.5 μ g/ml, Nr-CWS handles CD4 when concentration is 15 μ g/ml+After T cell 48 hours,
CD4+The significant raising of T cell proliferation (△p<0.001)。
Embodiment 2.Nr-CWS promotes CD4+The expression of T cell function of surface molecule CD25 and CD69
CD4+T cell presses 1 × 106/ ml cell density is inoculated with 96 orifice plates, every 100 μ l of hole.In 37 DEG C, 5%CO2Incubator
After middle culture 2 hours, the concentration of experimental group addition culture solution dissolution is Nr-CWS, the every 100 μ l of hole of 30 μ g/ml, if 3 multiple
Hole.RPMI 1640 culture medium, every 100 μ l of hole, if 3 multiple holes is added in control group.The control group that is unstained is made equally to locate with control group
Reason, but do not dye.In 37 DEG C, 5%CO2Incubator in cultivate 24 hours and 48 hours.Collect each group CD4+T cell is marked respectively
Remember anti-CD4, anti-CD25 and anti-CD69 streaming fluorescence antibody, then wash away unbonded dyestuff, 500 μ l's of preparation is thin
Born of the same parents' suspension.Using flow cytometer detection CD4+The expression of T cell function of surface molecule CD25 and CD69.Wherein, using BD
FACSDiva software collects at least 10000 cells.
As a result (see Fig. 2, wherein Fig. 2A 1 and Fig. 2A 2 is 24 hours, and Fig. 2 B1 and Fig. 2 B2 are 48 hours) display, Nr-CWS
Handle CD4+After T cell 24 hours, CD4+T cell function of surface molecule CD25 and CD69 expression are compared with the control group without obvious
Difference (p > 0.05)；After processing 48 hours, CD4+T cell function of surface molecule CD25 and CD69 expression are equal compared with the control group
It is significant to increase (* p<0.05).
Embodiment 3.Nr-CWS promotes CD4+The expression of T cell TNF-α, IL-2, IL-5
CD4+T cell presses 1 × 106/ ml cell density is inoculated with 96 orifice plates, every 100 μ l of hole.In 37 DEG C, 5%CO2Incubator
After middle culture 2 hours, the concentration of experimental group addition culture solution dissolution is Nr-CWS, the every 100 μ l of hole of 15 μ g/ml, if 3 multiple
Hole.RPMI 1640 culture medium, every 100 μ l of hole, if 3 multiple holes is added in control group.In 37 DEG C, 5%CO2Incubator in cultivate
24 hours and 48 hours.Nr-CWS group and cellular control unit culture supernatant are collected, using BioLegend company
LEGENDplexTMMouse Th Cytokine Panel Kit detect cell culture supernatant in cytokine TNF-α,
IL-2, IL-4, IL-5 and IL-10.
As a result (see Fig. 3, wherein Fig. 3 A is 24 hours, and Fig. 3 B is 48 hours) display, Nr-CWS handle CD4+T cell 24 is small
Shi Hou, compared with the control group, TNF-α, IL-2, IL-4, IL-10 express equal no significant difference (p > 0.05) compared with the control group,
And IL-5 expression has notable difference (* p compared with the control group<0.05)；After processing 48 hours, compared with the control group, TNF-α, IL-
2 expressions significantly increase (* p<0.05), IL-4, IL-5, IL-10 express equal no significant difference (p > compared with the control group
0.05)。
More than, embodiments of the present invention are illustrated.But the present invention is not limited to above embodiment.It is all
Within the spirit and principles in the present invention, any modification, equivalent substitution, improvement and etc. done should be included in guarantor of the invention
Within the scope of shield.
Claims (10)
1. Lyopgized Nocardia rubra-cell Wall Skeleton is in preparation for promoting CD4+Purposes in the drug of T cell proliferation.
2. CD4 of the Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose+The purposes of T cell enhancer of proliferation.
3. a kind of external promotion CD4+The method of T cell proliferation, wherein give the CD4 of in vitro culture+T cell nocardia rubra
Cell wall skeleton.It is preferred that the concentration of Lyopgized Nocardia rubra-cell Wall Skeleton be 1-60 μ g/ml, further preferred 2-30 μ g/ml,
More preferable 3-15 μ g/ml.
4. Lyopgized Nocardia rubra-cell Wall Skeleton is in preparation for promoting CD4+T cell function of surface molecule CD25 or CD69 expression
Drug in purposes.
5. CD4 of the Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose+T cell function of surface molecule CD25 or CD69 table
Up to the purposes of promotor.
6. a kind of external promotion CD4+The method of T cell function of surface molecule CD25 or CD69 expression, wherein give in vitro culture
CD4+T cell Lyopgized Nocardia rubra-cell Wall Skeleton.It is preferred that the concentration of Lyopgized Nocardia rubra-cell Wall Skeleton is 1-60 μ g/
Ml, further preferred 2-30 μ g/ml, more preferable 3-15 μ g/ml.
7. Lyopgized Nocardia rubra-cell Wall Skeleton is in preparation for promoting CD4+The drug of T cell TNF-α, IL-5 or IL-2 expression
In purposes.
8. CD4 of the Lyopgized Nocardia rubra-cell Wall Skeleton as non-treatment purpose+T cell TNF-α, IL-5 or IL-2 expression promote
The purposes of agent.
9. a kind of external promotion CD4+The method of T cell TNF-α, IL-5 or IL-2 expression, wherein give the CD4 of in vitro culture+T
Cell Lyopgized Nocardia rubra-cell Wall Skeleton.It is preferred that the concentration of Lyopgized Nocardia rubra-cell Wall Skeleton is 1-60 μ g/ml, into one
Walk preferred 2-30 μ g/ml, more preferable 3-15 μ g/ml.
10. purposes as claimed in any one of claims 1-9 wherein or method, wherein nocardia rubra Nr-8206.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710304838.3A CN108815197A (en) | 2017-05-03 | 2017-05-03 | Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710304838.3A CN108815197A (en) | 2017-05-03 | 2017-05-03 | Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108815197A true CN108815197A (en) | 2018-11-16 |
Family
ID=64154029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710304838.3A Withdrawn CN108815197A (en) | 2017-05-03 | 2017-05-03 | Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815197A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020147472A1 (en) * | 2019-01-15 | 2020-07-23 | 辽宁格瑞仕特生物制药有限公司 | Product derived from rhodococcus ruber, and pharmaceutical use thereof |
| WO2020182181A1 (en) * | 2019-03-14 | 2020-09-17 | 辽宁格瑞仕特生物制药有限公司 | Use of nocardia rubra cell wall skeleton in treating white lesions on vulva |
| WO2021147899A1 (en) * | 2020-01-21 | 2021-07-29 | 辽宁格瑞仕特生物制药有限公司 | Use of rhodococcus ruber cell wall skeleton in regenerative medicine |
| CN114402064A (en) * | 2020-01-21 | 2022-04-26 | 辽宁格瑞仕特生物制药有限公司 | Use of nocardia rubra cell wall skeleton in regenerative medicine |
| CN115025128A (en) * | 2022-06-24 | 2022-09-09 | 辽宁格瑞仕特生物制药有限公司 | Application of nocardia rubra cell wall skeleton in treatment of cervical lesion |
-
2017
- 2017-05-03 CN CN201710304838.3A patent/CN108815197A/en not_active Withdrawn
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020147472A1 (en) * | 2019-01-15 | 2020-07-23 | 辽宁格瑞仕特生物制药有限公司 | Product derived from rhodococcus ruber, and pharmaceutical use thereof |
| WO2020182181A1 (en) * | 2019-03-14 | 2020-09-17 | 辽宁格瑞仕特生物制药有限公司 | Use of nocardia rubra cell wall skeleton in treating white lesions on vulva |
| CN112040962A (en) * | 2019-03-14 | 2020-12-04 | 辽宁格瑞仕特生物制药有限公司 | Application of nocardia rubra cell wall skeleton in treating white lesions of vulva |
| WO2021147899A1 (en) * | 2020-01-21 | 2021-07-29 | 辽宁格瑞仕特生物制药有限公司 | Use of rhodococcus ruber cell wall skeleton in regenerative medicine |
| CN114402064A (en) * | 2020-01-21 | 2022-04-26 | 辽宁格瑞仕特生物制药有限公司 | Use of nocardia rubra cell wall skeleton in regenerative medicine |
| CN115025128A (en) * | 2022-06-24 | 2022-09-09 | 辽宁格瑞仕特生物制药有限公司 | Application of nocardia rubra cell wall skeleton in treatment of cervical lesion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108815197A (en) | Lyopgized Nocardia rubra-cell Wall Skeleton is as CD4+The purposes of T cell enhancer of proliferation | |
| Krause et al. | Role of Candida in antibiotic-associated diarrhea | |
| Tabares et al. | Anti-protease and immunomodulatory activities of bacteria associated with Caribbean sponges | |
| Mane et al. | Adherence to buccal epithelial cells, enzymatic and hemolytic activities of Candida isolates from HIV-infected individuals | |
| Ali et al. | Antifungal effects of rhizospheric Bacillus species against bayberry twig blight pathogen Pestalotiopsis versicolor | |
| Kumar et al. | An actinomycete isolate from solitary wasp mud nest having strong antibacterial activity and kills the Candida cells due to the shrinkage and the cytosolic loss | |
| CN112899182B (en) | Lactobacillus crispatus capable of preventing and/or treating cervical squamous cell carcinoma | |
| CN108795859A (en) | Purposes of the Lyopgized Nocardia rubra-cell Wall Skeleton as natural killer cells enhancer of proliferation | |
| CN107937324A (en) | One plant of Lactobacillus crispatus and its application | |
| CN111019858B (en) | Feeding bacillus licheniformis for inhibiting bacterial biofilm formation and application thereof | |
| Zhou et al. | The predatory myxobacterium Citreicoccus inhibens gen. nov. sp. nov. showed antifungal activity and bacteriolytic property against phytopathogens | |
| CN108795860A (en) | Lyopgized Nocardia rubra-cell Wall Skeleton is as CD8+The purposes of T cell enhancer of proliferation | |
| Sreenadh et al. | In vitro evaluation of Weizmannia coagulans strain LMG S-31876 isolated from fermented rice for potential probiotic properties, safety assessment and technological properties | |
| CN108165506B (en) | Streptomyces aureoflavus and application thereof | |
| Everest et al. | Nocardia rhamnosiphila sp. nov., isolated from soil | |
| JP7358002B2 (en) | Bacillus bacteria, interleukin-22 production inducer, skin barrier function enhancer | |
| Heydari et al. | Coniochaeta fungus benefits from its intracellular bacteria to form biofilm and defend against other fungi | |
| Devi et al. | Screening of suitable culture media for growth, cultural and morphological characters of Pycnidia forming fungi | |
| JP2005503171A (en) | Cultivation and isolation of microorganisms from the natural environment and drug discovery from them | |
| Rodríguez-Díaz et al. | The Metagenomic Composition and Effects of Fecal-Microbe-Derived Extracellular Vesicles on Intestinal Permeability Depend on the Patient’s Disease | |
| Hatem et al. | Inhibition of the growth and development of potato early blight pathogen (Alternaria solani) by combining Penicillium chrysogenum VKM F-4876D with some strobilurin-, triazole-, and phenylpyrrole-based fungicides | |
| CN102839144B (en) | Construction method of anti-tuberculosis medicine high-throughput screening model | |
| WO2014038822A1 (en) | Paecilomyces variotii var. brunneolus gpp1101b, and preparation using same | |
| Meene et al. | A novel antimicrobial metabolite produced by Paenibacillus apiarius isolated from brackish water of Lake Balkhash in Kazakhstan | |
| CN108220236B (en) | Human NK cell line |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181116 |
|
| WW01 | Invention patent application withdrawn after publication |